Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

PURPOSE To evaluate dexamethasone pharmacokinetics after implantation of a sustained-release dexamethasone (DEX) intravitreal implant in nonvitrectomized and vitrectomized eyes. METHODS The right eyes of 25 rabbits underwent vitrectomy; contralateral eyes served as nonvitrectomy controls. The 0.7-mg DEX implant was injected into both eyes, and drug concentrations were determined in the vitreous humor and retina for 31 days (on days 2, 8, 15, 22, and 31). RESULTS DEX was present in nonvitrectomized and vitrectomized eyes for at least 31 days. There were no statistically significant differences in DEX concentration between nonvitrectomized and vitrectomized eyes at any time point (P > 0.05). The maximum concentration of DEX in nonvitrectomized versus vitrectomized eyes for vitreous humor was 791 ng/mL (day 22) versus 731 ng/mL (day 22), respectively, and for retina it was 4110 ng/mL (day 15) versus 3670 ng/mL (day 22), respectively. Mean absorption (AUC(0-tlast)) of dexamethasone in nonvitrectomized and vitrectomized eyes was not different for both the vitreous humor (13,600 vs. 15,000 ng/day/mL; P = 0.73) and retina (67,600 vs. 50,200 ng/day/mL; P = 0.47). CONCLUSIONS The vitreoretinal pharmacokinetic profiles were similar between nonvitrectomized and vitrectomized eyes. These observations are consistent with clinical findings of the DEX implant in patients who have undergone vitrectomy and should reduce concerns about the use of the DEX implant in eyes that have undergone vitrectomy.

[1]  H. Tabandeh,et al.  DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS , 2011, Retina.

[2]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[3]  S. Whitcup,et al.  Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. , 2010, Investigative ophthalmology & visual science.

[4]  K. Csaky,et al.  Vitreous VEGF clearance is increased after vitrectomy. , 2010, Investigative ophthalmology & visual science.

[5]  E. Stefánsson,et al.  Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  George A. Williams,et al.  Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. , 2009, American journal of ophthalmology.

[7]  Chang-Hao Yang,et al.  BEVACIZUMAB PRETREATMENT IN VITRECTOMY WITH SILICONE OIL FOR SEVERE DIABETIC RETINOPATHY , 2009, Retina.

[8]  M. Naud,et al.  Poly-epsilon-caprolactone intravitreous devices: an in vivo study. , 2009, Investigative ophthalmology & visual science.

[9]  J. Haller,et al.  EVALUATION OF THE SAFETY AND PERFORMANCE OF AN APPLICATOR FOR A NOVEL INTRAVITREAL DEXAMETHASONE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF MACULAR EDEMA , 2009, Retina.

[10]  A. Neubauer,et al.  LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA , 2008, Retina.

[11]  P. A. Pearson,et al.  Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. , 2008, Archives of ophthalmology.

[12]  S. Pileri,et al.  Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies , 2008, Journal of Clinical Pathology.

[13]  A. Antoszyk,et al.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. , 2008, American journal of ophthalmology.

[14]  D. Laidlaw,et al.  Vitrectomy for diabetic macular oedema , 2008, Eye.

[15]  Yuan-Yuan Shi,et al.  Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[16]  George A. Williams,et al.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. , 2007, Archives of ophthalmology.

[17]  Manju Patel,et al.  Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[18]  P. A. Pearson,et al.  Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. , 2006, Ophthalmology.

[19]  S. Fialho,et al.  Safety and Pharmacokinetics of an Intravitreal Biodegradable Implant of Dexamethasone Acetate in Rabbit Eyes , 2006, Current eye research.

[20]  H. Chin,et al.  DIFFERENCE IN CLEARANCE OF INTRAVITREAL TRIAMCINOLONE ACETONIDE BETWEEN VITRECTOMIZED AND NONVITRECTOMIZED EYES , 2005, Retina.

[21]  J. Dissel,et al.  Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  S. Androudi,et al.  Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis , 2005, Journal of cataract and refractive surgery.

[23]  Peter Wiedemann,et al.  Drug delivery systems for vitreoretinal diseases , 2004, Progress in Retinal and Eye Research.

[24]  T. Friberg,et al.  Surgical treatments of central retinal vein occlusion , 2003, Seminars in ophthalmology.

[25]  D. Maurice,et al.  Review: practical issues in intravitreal drug delivery. , 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[26]  J. V. van Meurs,et al.  High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. , 1999, American journal of ophthalmology.

[27]  P. Arrigg,et al.  The role of vitrectomy for diabetic retinopathy. , 1998, Journal of the American Optometric Association.

[28]  K. Tojo,et al.  Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. , 1998, Biological & pharmaceutical bulletin.

[29]  P. A. Pearson,et al.  An intravitreal device providing sustained release of cyclosporine and dexamethasone. , 1994, Current eye research.

[30]  D. D’Amico,et al.  Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. , 1992, Archives of ophthalmology.

[31]  David B. Rorabacher,et al.  Statistical treatment for rejection of deviant values: critical values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level , 1991 .

[32]  L. B. Wingard,et al.  Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. , 1985, Ophthalmology.

[33]  J W Shell,et al.  Ophthalmic drug delivery systems , 1984, Survey of ophthalmology.

[34]  R. Machemer,et al.  The clearance of intravitreal triamcinolone acetonide. , 1982, American journal of ophthalmology.

[35]  G. Peyman,et al.  Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. , 1974, Archives of ophthalmology.

[36]  B. Saville,et al.  Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. , 1997, Current eye research.

[37]  M. Blumenkranz,et al.  Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. , 1985, Ophthalmology.

[38]  Cunxian Song,et al.  Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Pharmacokinetics and Tolerance Study of Intravitreal Injection of Dexamethasone-loaded Nanoparticles in Rabbits , 2022 .